<DOC>
	<DOC>NCT00004406</DOC>
	<brief_summary>OBJECTIVES: I. Determine the effect of human parathyroid hormone (1-34) on bone mass in middle-aged men with idiopathic osteoporosis.</brief_summary>
	<brief_title>Randomized Study of Human Parathyroid Hormone in Middle-Aged Men With Idiopathic Osteoporosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. All patients self-administer daily subcutaneous injections of human parathyroid hormone (1-34) or placebo for a period of 2.5 years. Patients are followed regularly for unacceptable toxicities. Completion date provided represents the completion date of the grant per OOPD records</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA: Disease Characteristics Osteoporosis as defined by: Bone mineral density at the lumbar spine or femoral neck that is 2.5 standard deviations below peak bone mass reference value (T score less than 2.5) No family history of male osteoporosis No other metabolic bone disease Prior/Concurrent Therapy Endocrine therapy: No concurrent glucocorticoid therapy No prior steroid use Surgery: No prior gastrointestinal tract surgery Other: No prior or concurrent anticonvulsant therapy Patient Characteristics Hematopoietic: Normal CBC Hepatic: Normal liver function Renal: Normal renal function Other: Normal thyroid function Normal adrenal function Normal gonadal status No myeloma or other malignancy No alcoholism, hypercortisolism or diabetes mellitus No gastrointestinal tract disease or disorder associated with malabsorption</criteria>
	<gender>Male</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>disease-related problem/condition</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>rare disease</keyword>
</DOC>